Cargando…

CMV hyperimmune globulin as salvage therapy for recurrent or refractory CMV infection in children undergoing hematopoietic stem cell transplantation

Cytomegalovirus (CMV) is a major cause of allogeneic hematopoietic stem cell transplant (HSCT)-related morbidity and mortality. Treatment failure continues to be a major issue in patients with CMV infection due to both drug resistance and intolerance. This single-center brief retrospective analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panesso, Melissa, Uría, María Luz, Renedo, Berta, Esperalba, Juliana, Benítez-Carabante, María Isabel, Mendoza-Palomar, Natalia, Alonso, Laura, Oliveras, Maria, Diaz-de-Heredia, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405925/ https://www.ncbi.nlm.nih.gov/pubmed/37554153 http://dx.doi.org/10.3389/fped.2023.1197828

Ejemplares similares

Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
por: Basic-Jukic, Nikolina
Publicado: (2020)

Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin
por: Patel, Samir J., et al.
Publicado: (2014)

1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Artau, Annette, et al.
Publicado: (2018)

940. The use of a commercially available CMV T Cell Immunity Panel to Assess the Risk of CMV Infections in Hematopoietic Cell Transplant Recipients with Low Level CMV Viremia
por: Khawaja, Fareed, et al.
Publicado: (2021)

CMV in Hematopoietic Stem Cell Transplantation
por: de la Cámara, Rafael
Publicado: (2016)

1897. Letermovir Salvage for Complicated Cases of Resistant CMV
por: Turner, Nicholas, et al.
Publicado: (2018)

Hyperimmune Globulins for the Management of Infectious Diseases
por: Pati, Ilaria, et al.
Publicado: (2023)

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
por: Piñana, José Luis, et al.
Publicado: (2019)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2023)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

Successful Use of Heterologous CMV-Reactive T Lymphocyte to Treat Severe Refractory Cytomegalovirus (CMV) Infection in a Liver Transplanted Patient: Correlation of the Host Antiviral Immune Reconstitution with CMV Viral Load and CMV miRNome
por: Miele, Monica, et al.
Publicado: (2021)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV
por: Carbone, Javier
Publicado: (2016)

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, I P, et al.
Publicado: (2018)

13. CMV Reactivation in refractory ANCA-associated vasculitis
por: Hassan, Neelam, et al.
Publicado: (2019)

New Treatment Options for Refractory/Resistant CMV Infection
por: Walti, Carla Simone, et al.
Publicado: (2023)

CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
por: Schulz, Uwe, et al.
Publicado: (2016)

The Impact of High CMV Viral Load and Refractory CMV Infection on Pediatric HSCT Recipients with Underlying Non-Malignant Disorder
por: Szmit, Zofia, et al.
Publicado: (2022)

Treatment of Cytomegalovirus Infection with Cidofovir and CMV Immune Globulin in a Lung Transplant Recipient
por: Wilkens, Heinrike, et al.
Publicado: (2016)

Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity
por: Kirisri, Similan, et al.
Publicado: (2021)

Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1–Infected Individuals
por: Aichelburg, Maximilian C., et al.
Publicado: (2015)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
por: He, Ran, et al.
Publicado: (2011)

Stimulatory Effect of CMV Immunoglobulin on Innate Immunity and on the Immunogenicity of CMV Antigens
por: Deml, Ludwig, et al.
Publicado: (2021)

Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment
por: Valle-T-Figueras, José María, et al.
Publicado: (2021)

431 Incidence, Burden and Cost Analysis of CMV Reactivation after Use of Anti-Thymocyte Globulin in Resource-Limited Setting
por: Chitasombat, Maria N., et al.
Publicado: (2014)

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Ariza-Heredia, Ella J, et al.
Publicado: (2023)

Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors
por: Pita-Lopez, María Luisa, et al.
Publicado: (2009)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

CMV-specific T-Cells for Treatment of CMV Infection after Hematopoietic Stem Cell Transplantation in a Pediatric Case: First Application in Turkey
por: Celilova, Sevil, et al.
Publicado: (2020)

CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis
por: Goodman, A. L., et al.
Publicado: (2014)

GAMMA GLOBULIN TURNOVER IN RABBITS BEFORE AND DURING HYPERIMMUNIZATION
por: Andersen, Stig Bryde, et al.
Publicado: (1964)

Herd immunity: hyperimmune globulins for the 21st century
por: Elliott, Sarah TC, et al.
Publicado: (2018)

How Do Donor-Recipient CMV Serostatus and Post-Hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients?
por: Vaezi, Mohammad, et al.
Publicado: (2017)

The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With Increased Survival in CMV Positive Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation
por: Grosso, Dolores, et al.
Publicado: (2019)

491. Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2022)

CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies
por: Jakharia, Niyati, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bva8ht3ehtkaanqu24jqulsm4v